美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察

Clinical observation of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure

目的研究分析美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察。方法选取本院2015年1月～2016年12月收治的80例冠心病心力衰竭患者为研究对象，随机分为对照组和实验组各为40例。对照组进行常规治疗，包括给予利尿剂、血管紧张素转化酶抑制剂等治疗，实验组在此基础上进行曲美他嗪联合美托洛尔治疗。比较分析两组患者的治疗效果。结果治疗后，实验组患者中，5例患者无效。对照组中，14例患者无效，实验组治疗有效率（87.5%）显著高于对照组（65.0%），差异具有统计学意义（P<0.05）。治疗后，实验组患者的LVEF为（50.4±7.7）％，对照组患者LVEF为（45.1±7.0）％。另外，实验组患者的LVEDD以及LVESD指标以及LVEF均优于对照组，差异具有统计学意义（P<0.05）。结论曲美他嗪联合美托洛尔治疗冠心病心力衰竭的临床效果较好，能在一定程度上提高治疗有效率，具有临床进一步推广和应用的意义。

Objective To study and analyze the clinical efficacy of metoprolol combined with trimetazidine in the treatment of coronary heartdisease and heart failure.Methods80patients with coronary heart disease and heart failure treated in our hospital from January2015to December2016were selected and randomly divided into the control group and the experimental group,with40cases in each group.The control group receivedroutine treatment,including diuretics and angiotensin converting enzyme inhibitors,and the experimental group was treated with trimetazidinecombined with metoprolol.The therapeutic effects of the two groups were compared and analyzed.Results After the corresponding treatment,5patients in the experimental group were invalid.In the control group,14patients were ineffective.The effective rate of treatment in the experimentalgroup(87.5%)was significantly higher than that in the control group(65.0%),the differences were statistically significant(P<0.05).After treatment,the LVEF in the experimental group was(50.4±7.7)%,and the LVEF in the control group was(45.1±7.0)%.In addition,the LVEDD and LVESDindexes and LVEF in the experimental group were better than those in the control group,the differences were statistically significant(P<0.05).Conclusion The clinical effect of trimetazidine combined with metoprolol in the treatment of coronary heart disease and heart failure is better.It canimprove the efficiency of treatment to some extent,and has the significance of further promotion and application.